发布求助
文献互助 智能选刊 最新文献

Клиническая онкология最新文献

筛选
英文 中文
Особливості впливу метаболічного синдрому на агресивність перебігу раку передміхурової залози 代谢综合征对前列腺癌侵袭性影响的特点
Клиническая онкология Pub Date : 2023-01-01 DOI: 10.32471/clinicaloncology.2663-466x.50-2.30779
{"title":"Особливості впливу метаболічного синдрому на агресивність перебігу раку передміхурової залози","authors":"","doi":"10.32471/clinicaloncology.2663-466x.50-2.30779","DOIUrl":"https://doi.org/10.32471/clinicaloncology.2663-466x.50-2.30779","url":null,"abstract":"Summary. The purpose of the study was to investigate the specifics of the clinical and morphological course of prostate cancer (PCa) in patients with metabolic syndrome (MS) and its influence on the spread of the metastatic process. Materials and methods. The study included 79 patients with locally advanced PCa who underwent inpatient treatment in the period from 2015 to 2020 in plastic and reconstructive department of National cancer institute of Ukraine and undergo further outpatient observation, diagnosis and treatment during the time before the development of bone metastasis (BM) from the moment of radical prostatectomy (RP), among which MS was diagnosed in 40 (50.6%) and absent in 39 (49.4%). The average age of the patients was: 69 (59–80) years. Patients participated in the study with existing MS were divided into 2 studied groups: 17 (21.5%) with moderate risk (Grade group 2, 3) and 23 (29.1%) with high risk (Grade group 4, 5) of disease progression, in contrast to patients without MS: 20 (25.3%) with Grade group 2, 3 and 19 (24.1%) with Grade group 4, 5. The average initial level of total PSA in patients with MS and Grade group 2, 3 was: 16.35 ng/ml, Grade group 4, 5 — 23.75 ng/ml. In patients without MS with Grade group 2, 3 — 14 ng/ml, Grade group 4, 5 — 21.45 ng/ml. Results. Among 79 study participants, after RP, 35 (44.3%) were diagnosed with the development of bone and visceral metastases, in contrast to 44 (55.7%) without metastases. Among 35 patients with the development of BM — 27 (77.1%) with MS, 8 (22.9%) — no signs of MS. BM was combined with visceral metastases in 17 (48.5%) patients, MS was found in most cases of this cohort of 11 (64.7%) patients. BM in the subgroup of moderate risk (Gleason","PeriodicalId":487505,"journal":{"name":"Клиническая онкология","volume":"18 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136207053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Особливості перебігу раку грудної залози з низьким рівнем експресії HER2/neu HER2/neu 低表达乳腺癌的特征
Клиническая онкология Pub Date : 2023-01-01 DOI: 10.32471/clinicaloncology.2663-466x.50-2.30634
{"title":"Особливості перебігу раку грудної залози з низьким рівнем експресії HER2/neu","authors":"","doi":"10.32471/clinicaloncology.2663-466x.50-2.30634","DOIUrl":"https://doi.org/10.32471/clinicaloncology.2663-466x.50-2.30634","url":null,"abstract":"early disease stages. It was determined that the frequency of BC recurrences was higher in patients with greater HER2 expression, but it was not statistically significant, p >0.05. Conclusions. The obtained results propose general concepts of HER2-low BC and require further study","PeriodicalId":487505,"journal":{"name":"Клиническая онкология","volume":"64 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136207054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Вибір ад’ювантного лікування раку ендометрія ІІІА–С стадій IIIA-C 期子宫内膜癌辅助治疗的选择
Клиническая онкология Pub Date : 2023-01-01 DOI: 10.32471/clinicaloncology.2663-466x.50-2.30530
{"title":"Вибір ад’ювантного лікування раку ендометрія ІІІА–С стадій","authors":"","doi":"10.32471/clinicaloncology.2663-466x.50-2.30530","DOIUrl":"https://doi.org/10.32471/clinicaloncology.2663-466x.50-2.30530","url":null,"abstract":"","PeriodicalId":487505,"journal":{"name":"Клиническая онкология","volume":"369 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136207055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Формування радіойодорезистентності у хворих на диференційований рак щитоподібної залози та можливості її прогнозування. Використані дані літератури та власних досліджень 分化型甲状腺癌患者放射性碘耐药性的形成及其预测的可能性。采用了文献和自身研究的数据
Клиническая онкология Pub Date : 2023-01-01 DOI: 10.32471/clinicaloncology.2663-466x.50-2.30652
{"title":"Формування радіойодорезистентності у хворих на диференційований рак щитоподібної залози та можливості її прогнозування. Використані дані літератури та власних досліджень","authors":"","doi":"10.32471/clinicaloncology.2663-466x.50-2.30652","DOIUrl":"https://doi.org/10.32471/clinicaloncology.2663-466x.50-2.30652","url":null,"abstract":"","PeriodicalId":487505,"journal":{"name":"Клиническая онкология","volume":"82 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136208495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Клінічна характеристика, особливості лікування та досягнення кінцевих точок, оцінені в реальній клінічній практиці застосування талазопарібу у пацієнтів із HER2-негативним BRCA-асоційованим раком грудної залози 在实际临床实践中评估塔拉帕利治疗HER2阴性BRCA相关乳腺癌患者的临床特征、治疗特点和终点
Клиническая онкология Pub Date : 2023-01-01 DOI: 10.32471/clinicaloncology.2663-466x.50-2.30589
{"title":"Клінічна характеристика, особливості лікування та досягнення кінцевих точок, оцінені в реальній клінічній практиці застосування талазопарібу у пацієнтів із HER2-негативним BRCA-асоційованим раком грудної залози","authors":"","doi":"10.32471/clinicaloncology.2663-466x.50-2.30589","DOIUrl":"https://doi.org/10.32471/clinicaloncology.2663-466x.50-2.30589","url":null,"abstract":"","PeriodicalId":487505,"journal":{"name":"Клиническая онкология","volume":"32 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136208712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Випадок метахромної і синхронної вторинної меланоми шкіри 一例变色同步继发性皮肤黑色素瘤病例
Клиническая онкология Pub Date : 2023-01-01 DOI: 10.32471/clinicaloncology.2663-466x.50-2.30751
{"title":"Випадок метахромної і синхронної вторинної меланоми шкіри","authors":"","doi":"10.32471/clinicaloncology.2663-466x.50-2.30751","DOIUrl":"https://doi.org/10.32471/clinicaloncology.2663-466x.50-2.30751","url":null,"abstract":"","PeriodicalId":487505,"journal":{"name":"Клиническая онкология","volume":"2 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136210016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Найвагоміші досягнення наукових досліджень державного некомерційного підприємства «Національний інститут раку» у 2022р. 美国国家癌症研究所 2022 年最重要的研究成果。
Клиническая онкология Pub Date : 2023-01-01 DOI: 10.32471/clinicaloncology.2663-466x.50-2.30766
{"title":"Найвагоміші досягнення наукових досліджень державного некомерційного підприємства «Національний інститут раку» у 2022р.","authors":"","doi":"10.32471/clinicaloncology.2663-466x.50-2.30766","DOIUrl":"https://doi.org/10.32471/clinicaloncology.2663-466x.50-2.30766","url":null,"abstract":"","PeriodicalId":487505,"journal":{"name":"Клиническая онкология","volume":"45 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136207043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Метастази раку в лімфатичні вузли шиї без встановленого первинного вогнища 癌症转移至颈部淋巴结，但未确定原发病灶
Клиническая онкология Pub Date : 2023-01-01 DOI: 10.32471/clinicaloncology.2663-466x.50-2.30486
{"title":"Метастази раку в лімфатичні вузли шиї без встановленого первинного вогнища","authors":"","doi":"10.32471/clinicaloncology.2663-466x.50-2.30486","DOIUrl":"https://doi.org/10.32471/clinicaloncology.2663-466x.50-2.30486","url":null,"abstract":"","PeriodicalId":487505,"journal":{"name":"Клиническая онкология","volume":"34 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136207052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Первинні Т-клітинні лімфоми шкіри: класифікація, діагностика, лікування (огляд літератури) 皮肤原发性T细胞淋巴瘤：分类、诊断和治疗（文献综述）
Клиническая онкология Pub Date : 2023-01-01 DOI: 10.32471/clinicaloncology.2663-466x.50-2.30797
{"title":"Первинні Т-клітинні лімфоми шкіри: класифікація, діагностика, лікування (огляд літератури)","authors":"","doi":"10.32471/clinicaloncology.2663-466x.50-2.30797","DOIUrl":"https://doi.org/10.32471/clinicaloncology.2663-466x.50-2.30797","url":null,"abstract":"pertinent issues is the diagnosis and treatment of T-cell skin lymphomas using a diagnostic panel of a wide range of modern examination methods (histological, immunological, molecular-genetic), which allow the correct determination of prognosis and optimization of therapy using individualized treatment approaches with the newest methods","PeriodicalId":487505,"journal":{"name":"Клиническая онкология","volume":"17 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136207051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Особливості хірургічного етапу лікування раку грудної залози за наявності згрупованих мікрокальцифікатів 出现成组微钙化时乳腺癌手术治疗阶段的特征
Клиническая онкология Pub Date : 2023-01-01 DOI: 10.32471/clinicaloncology.2663-466x.50-2.30837
{"title":"Особливості хірургічного етапу лікування раку грудної залози за наявності згрупованих мікрокальцифікатів","authors":"","doi":"10.32471/clinicaloncology.2663-466x.50-2.30837","DOIUrl":"https://doi.org/10.32471/clinicaloncology.2663-466x.50-2.30837","url":null,"abstract":"","PeriodicalId":487505,"journal":{"name":"Клиническая онкология","volume":"7 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136208502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信